News

Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty
U.S. President Donald Trump heads to Pittsburgh, Pennsylvania on Friday to headline a rally to celebrate Nippon Steel's ...
Trump administration ending multiple HIV vaccine studies, scientists and officials say
The Trump administration has moved to end funding for a broad swath of HIV vaccine research, saying current approaches are ...
Gilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold?
GILD stock jumps 21.1% YTD as HIV dominance, lenacapavir progress, and liver drug approval offset oncology pressures. However ...
Stocktwits on MSN21h
Gilead Eyes HIV Drug Rollout In Low-Income Countries Despite Funding Uncertainty, Says Report: Retail Holds Onto Bearish Stance
Shares of Gilead Sciences, Inc. (GILD) were in the spotlight on Friday morning after the company reportedly said that it ...